

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS DEEPENS R&D
COLLABORATION WITH LILLY

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced that the Company has entered into a strategic research collaboration and license agreement (the “**Agreement**”) with Eli Lilly and Company (“**Lilly**”), a leading global pharmaceutical company. Under the Agreement, the two companies will collaborate on the discovery and development of innovative medicines across multiple targets, advancing novel drug candidates with global potential.

To the best knowledge and belief of the Company, Lilly and its ultimate beneficial owner are independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

This is a voluntary announcement made by the Company. The Group cannot guarantee that a product will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 24 June 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

ABBISKO THERAPEUTICS DEEPENS R&D COLLABORATION WITH LILLY

On 24 June 2026, Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”) announced that it has entered into a strategic research collaboration and license agreement (the “**Agreement**”) with Eli Lilly and Company (“**Lilly**”), a leading global pharmaceutical company. Under the Agreement, the two companies will collaborate on the discovery and development of innovative medicines across multiple targets, advancing novel drug candidates with global potential.

By leveraging their respective strengths in drug discovery, research and development, and global drug development, Abbisko Therapeutics and Lilly aim to accelerate the advancement of innovative therapeutic programs and bring new treatment options to patients worldwide.

Under the terms of the Agreement, Abbisko Therapeutics will utilize its early-stage drug discovery platform, innovative R&D ecosystem, and extensive development expertise to conduct discovery and early development activities for novel drug programs directed against disease targets selected by Lilly. Abbisko Therapeutics will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments totalling up to approximately US\$1.9 billion. In addition, Abbisko Therapeutics will be eligible to receive tiered royalties based on annual net sales of products arising from this collaboration.

In 2022, Abbisko Therapeutics and Lilly entered into a global collaboration and exclusive license agreement to collaborate on the discovery, development, and potential commercialization of a novel small-molecule therapeutic.

Supported by its continually evolving drug discovery platform, extensive R&D experience and proven execution capabilities, Abbisko Therapeutics has continued to expand its global partnership network and accelerate the translation of scientific innovation into therapeutic advances. This collaboration with Lilly is expected to advance multiple innovative programs and further strengthen Abbisko’s global innovation strategy and long-term value creation potential.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.